Overview

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Status:
Recruiting
Trial end date:
2026-03-25
Target enrollment:
Participant gender:
Summary
Select the appropriate population for adding CDK4/6 inhibitors therapy in high risk early HR+/HER2-breast cancer based on molecular detection
Phase:
Phase 4
Details
Lead Sponsor:
Yongsheng Wang
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Letrozole